Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,340
  • Shares Outstanding, K 4,999
  • Annual Sales, $ 40,500 K
  • Annual Income, $ -69,190 K
  • EBIT $ -72 M
  • EBITDA $ -74 M
  • 60-Month Beta 0.45
  • Price/Sales 3.59
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 320.88%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 986.44% on 11/28/25
  • IV Low 0.00% on 12/26/25
  • Expected Move (DTE 19) 0.09 (0.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 152
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,503
  • Open Int (30-Day) 9,615
  • Expected Range 27.59 to 27.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.89
  • Number of Estimates 4
  • High Estimate -1.56
  • Low Estimate -3.72
  • Prior Year -2.75
  • Growth Rate Est. (year over year) -5.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.30 +6.50%
on 11/28/25
29.39 -1.07%
on 12/19/25
+1.53 (+5.57%)
since 11/26/25
3-Month
7.37 +294.50%
on 09/29/25
29.39 -1.07%
on 12/19/25
+21.51 (+284.08%)
since 09/26/25
52-Week
5.21 +458.06%
on 08/13/25
38.00 -23.49%
on 12/27/24
-6.42 (-18.10%)
since 12/26/24

Most Recent Stories

More News
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

ALEX : 20.66 (+0.05%)
UBFO : 10.13 (-0.88%)
MRSN : 29.08 (-0.09%)
UDMY : 5.95 (+0.17%)
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

RYI : 26.27 (+0.34%)
MRSN : 29.08 (-0.09%)
CDTX : 220.80 (-0.03%)
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm continues to investigate Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced...

MRSN : 29.08 (-0.09%)
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

MRSN : 29.08 (-0.09%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI

NEW YORK , Dec. 8, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

RYI : 26.27 (+0.34%)
MRSN : 29.08 (-0.09%)
SMLR : 16.69 (-3.78%)
CDTX : 220.80 (-0.03%)
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

SEMR : 11.86 (+0.08%)
MRSN : 29.08 (-0.09%)
EXAS : 101.57 (+0.03%)
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN

NEW YORK , Nov. 27, 2025 / PRNewswire/ --

SEE : 41.39 (+0.07%)
MRSN : 29.08 (-0.09%)
EXAS : 101.57 (+0.03%)
CDTX : 220.80 (-0.03%)
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

SEE : 41.39 (+0.07%)
MRSN : 29.08 (-0.09%)
RPTX : 2.57 (+0.78%)
CDTX : 220.80 (-0.03%)
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics...

MRSN : 29.08 (-0.09%)
Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

HOLX : 74.50 (unch)
MRSN : 29.08 (-0.09%)
CDTX : 220.80 (-0.03%)

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 29.42
2nd Resistance Point 29.28
1st Resistance Point 29.18
Last Price 29.08
1st Support Level 28.94
2nd Support Level 28.81
3rd Support Level 28.70

See More

52-Week High 38.00
Last Price 29.08
Fibonacci 61.8% 25.47
Fibonacci 50% 21.60
Fibonacci 38.2% 17.74
52-Week Low 5.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar